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Pharmacological stabilization of hypoxia-inducible factor (HIF) through prolyl hydroxylase (PHD) inhibition limits
mucosal damage associated with models of murine colitis. However, little is known about how PHD inhibitors (PHDi)
influence systemic immune function duringmucosal inflammation or the relative importance of immunological changes
to mucosal protection. We hypothesized that PHDi enhances systemic innate immune responses to colitis-associated
bacteremia.Micewith colitis inducedby trinitrobenzene sulfonic acidwere treatedwithAKB-4924, a newHIF-1 isoform-
predominantPHDi, andclinical, immunological, andbiochemical endpointswereassessed.AdministrationofAKB-4924
led to significantly reduced weight loss and disease activity compared with vehicle controls. Treated groups were
pyrexic but did not become subsequently hypothermic. PHDi treatment augmented epithelial barrier function and led to
an approximately 50-fold reduction in serum endotoxin during colitis. AKB-4924 also decreased cytokines involved in
pyrogenesis and hypothermia, significantly reducing serum levels of interleukin (IL)-1b, IL-6, and tumor necrosis factor
(TNF)-a while increasing IL-10. Treatment offered no protection against colitis in epithelial-specific HIF-1a-deficient
mice, strongly implicatingepithelialHIF-1aas the tissue target forAKB-4924-mediatedprotection. Taken together, these
results indicate that inhibition of prolyl hydroxylase with AKB-4924 enhances innate immunity and identifies that the
epithelium is a central site of inflammatory protection afforded by PHDi in murine colitis.
INTRODUCTION
Inflammatory bowel diseases (IBD) are characterized by
repeated wounding of the mucosa and loss of the intestinal
epithelial barrier function.1 This leads to the passage of bacteria
or bacterial products from the lumen to the serosa and into
the blood, resulting in systemic bacteremia and endotoxemia,
which are both common features of IBD.2–4 Prolyl hydroxylase
(PHD) inhibition has been shown to reduce disease severity in
murine models of colitis on several levels of clinical scoring.5–9
The observed mucosal protection is a consequence of
PHD-2 sensitive hypoxia-inducible factor (HIF) stabilization10
and PHD-1 sensitive nuclear factor-kB activation,11 as the
pan-prolyl hydroxylase inhibitors employed in these studies,
such as dimethyloxallyl glycine (DMOG), activate both
pathways. This mucosal protection in murine colitis models
is multi-factorial, and the roles for compensatory epithelial
barrier pathways,6 anti-apoptotic regulation,8 and the
promotion of restitution and wound healing7 have been
demonstrated.
Recent studies have demonstrated the importance of HIF in
immune cell responses to infection. Neutrophils obtained from
patients with heterozygous germline mutations in the von
Hippel Lindau protein display increased survival times and
enhanced phagocytic capacity.12 In vitro studies have demon-
strated that stabilization of HIF with DMOG prolonged
neutrophil survival13 and HIF stabilization by hypoxic
incubation enhanced bacterial phagocytosis by neutrophils14
and macrophages.15 Further, DMOG treatment ameliorated
disease in a murine model of endotoxic shock, through
suppression of inflammatory cytokines and enhanced IL-10
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production.16 More recently, a predominantly HIF-1-specific
PHD inhibitor (PHDi), AKB-4924, has been developed.17
Treatment with AKB-4924 enhanced the bactericidal capacity
of keratinocytes against a range of skin pathogens in mouse
models of infection.17 Importantly, the concentrations that
were effective were orders of magnitude less than those
previously observed with other PHDis (DMOG and FG
(functional group)-class compounds), which typically suffer
from poor solubility. Thus, it is likely that PHDi treatment in
murine models of colitis also drive an innate cell response,
driven by HIF stabilization in immune cells. However, as
previous studies into mucosal protection by PHDis in colitis
have focused primarily on epithelial cells,6,8,9 the importance of
these processes have not yet been defined.
Here, we hypothesized that subcutaneous administration
of AKB-4924 enhances innate cell responses in a mouse
colitis model. Employing the chemical induction of colitis
using trinitrobenzene sulfonic acid (TNBS), we assessed the
systemic inflammatory response to bacteremia associated with
intestinal inflammation. We examined inflammatory signaling
in innate barrier cells and epithelial-specific HIF-1a-deficient
mice. We also compared the relative importance of
HIF-mediated epithelial barrier responses and HIF-driven
innate cell activity. Our results suggest that PHDi treatment
stabilizes HIF and suppresses inflammatory signaling by an
epithelial mechanism that is critical for the mucosal protection
in models of colitis.
RESULTS
AKB-4924 reduces TNBS disease pathology
We first hypothesized that PHDi treatment would enhance
systemic immune cell responses to inflammation, particularly
those associated with intestinal epithelial barrier dysfunction in
a TNBS model of colitis. Initially, we examined the pyrogenic
response in TNBS colitic mice treated with AKB-4924,
a new HIF-1 isoform-predominant PHDi. Animals treated
with AKB-4924 showed reduced weight loss (Figures 1a,
Po0.01), attenuated colon shortening (Figures 1b, Po0.05) at
all the doses tested (0.3, 1, and 5mg kg 1), with as little as
0.3mg kg 1 AKB-4924 showing marked improvements in
each of these end points. Histologically, AKB-4924-treated
colitic animals showed quite significantly reduced tissue
damage compared with vehicle and decreased disease
activity indices (Figure 1c) and resulted in significantly
decreased disease activity scores at all the doses tested
(Figures 1d, Po0.01).
In the course of these studies, we examined core body
temperature as an indicator of disease severity. Interestingly,
there was no difference in the early pyrogenic response
(þ 1.1±0.56 1C at 6 h post TNBS induction, Po0.001
compared with vehicle control) to TNBS administration
between AKB-4924-treated and untreated animals
(Figure 1e). However, the subsequent hypothermic
response observed in untreated TNBS mice ( 1.65±
0.58 1C at 168 h post TNBS induction, Po0.001 compared
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Figure 1 Influence of AKB-4924 treatment on disease activity in trinitrobenzene sulfonic acid (TNBS) colitis. AKB-4924 (0, 0.3, 1.0 or 5.0mg kg 1 in
cyclodextrin vehicle) was administered subcutaneously on day  1 relative to TNBS or EtOH intrarectal lavage. (a) Weight was monitored daily as an
indicator of disease severity and normalized relative to initial weight and control animals. On day 7, animals were killed and colons were excised and
measured to assess (b) colon length. Panel (c) representsH&Estaining of (A) tissue isolated fromcontrol animals, (B) TNBSanimals treatedwith vehicle,
and (C) TNBS animal treatedwith AKB-4924. (d) Disease activity was assessed as sumof scoring (0–3) for colon thickening (colonweight/length), occult
blood, fecal pellet consistency, and percentage of weight loss. (e) Temperature was measured by infrared (IR) thermometer at t¼0, 6, 12, and 24 h and
then at 24-h intervals until killing. N¼ 6, *Po0.05, **Po0.01, ***Po0.001, #Po0.05, analysis of variance (a, e), two-tailed, Student’s t-test (b, d).
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with EtOH control) was not observed in the AKB-4924-treated
groups ( 0.03±0.50 1C, non-significant compared with
EtOH control), suggesting that PHDi influences the
systemic inflammatory response in TNBS colitis.
AKB-4924 alters endogenous pyrogen responses in TNBS
colitis
Guided by these altered hypothermic responses in PHDi-
treated animals, we investigated serum levels of endogenous
pyrogens over the course of 1-week TNBS colitis progression.
At the peak of acute disease (measured byweight loss, day 2 post
TNBS), colitic animals had significantly elevated levels of IL-1b
(21±9-fold, Figure 2a, Po0.01). At day 2, there was no
significant reduction of IL-1b in PHDi-treated animals.
However, at days 3 and 7, PHDi strongly reduced IL-1b
expression (Po0.01) compared with placebo-exposed colitic
mice. Similarly, TNBS colitis animals had significant increases
in IL-6 (33±11-fold, Figure 2b) compared with controls. By
day 3, PHDi treatment significantly reduced IL-6 (61±5%
reduction, Po0.01), and by day 7, levels were back to baseline
and were comparable with non-TNBS controls (97±3%
reduction, Po0.01). TNF-a was significantly increased in
TNBS-treated animals by day 2, and increased at day 3 (4±
1-fold, Po0.05) and day 7 (12±5-fold, Po0.01) compared with
controls (Figure 2c). PHDi treatment resulted in a significant
reduction in TNF-a by day 3 andwas reduced by day 7 (76±8%
reduction, Po0.01). As IL-10 is an anti-inflammatory cytokine
and may suppress the hypothermic response,18 we investigated
serum levels and found that they were significantly increased in
PHDi-treated TNBS animals comparedwith untreated controls
from days 2–7 (Figure 2d). In addition, we examined whole-
colon homogenates for cytokine levels at day 7 and found
significant increases in IL-1b, IL-6, and TNF-a in TNBS
animals, which were again ameliorated by PHDi treatment in a
concentration-dependent manner (Figure 2e–g, Po0.01).
IL-10 was unchanged in colon homogenates (Figure 2h).
Such findings reveal that PHDi controls systemic pyrogenic
responses in murine colitis.
AKB-4924 significantly reduces intestinal permeability and
endotoxemia in TNBS colitis
We next assessed the influence of AKB-4924 on epithelial
barrier function. As PHDi pre-treatment did not prevent
pyrexia (fever) in TNBS colitic mice, we hypothesized that the
pyrexia observed was due to lipopolysaccharide (LPS) exposure
that occurred as a result of increased intestinal epithelial
permeability associated with acute colitis. To test this, we first
examined intestinal permeability in untreated and AKB-4924-
treated TNBS and control animals. TNBS animals had
increased intestinal permeability 2 days after administration
compared with untreated controls (Po0.01), and permeability
continued to increase up to 7 days (Figures 3a, Po0.01). PHDi
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Figure 2 Influence of AKB-4924 treatment on pyrogen levels in trinitrobenzene sulfonic acid (TNBS) colitis. AKB-4924 (5.0mg kg1 in cyclodextrin
vehicle) or vehicle-treated animalswere killed on day 2, 3, or 7 relative toTNBSorEtOH rectal lavage. Bloodwas collectedby cardiac puncture and serum
assayed in triplicate for each animal by multiplex enzyme-linked immunosorbent assay (ELISA) for (a) interleukin (IL)-1b, (b) IL-6, (c) tumor necrosis
factor (TNF)-a, and (d) IL-10.Onday7,whole-colon tissuewashomogenized in lysis buffer andassayedbyELISA for (e) IL-1b, (f) IL-6, (g) TNF-a, and (h)
IL-10. N¼6, *Po0.05, **Po0.01 two-tailed Student’s t-test.
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treatment significantly reduced both initial (day 2, Po0.05)
and later (days 3 and 7, Po0.01) increases in permeability. To
investigate whether such increases in permeability could result
in endotoxemia, we examined serum LPS levels. Untreated
TNBS colitic animals had significantly higher levels of serum
LPS than healthy control groups throughout the time course
(Figures 3b, Po0.01). Serum LPS levels were significantly
reduced (480%) in colitic animals administered AKB-4924 at
all time points tested (Po0.01).
We have previously demonstrated that HIF stabilization
promotes barrier function by enhancedmucosal wound healing
through mechanisms including induction of the HIF-1 target
genes intestinal trefoil factor (ITF)19 and 5’ecto-nucleotidase
(CD73).20 As shown in Figure 3c, enriched intestinal epithelial
cell preparations from AKB-4924-treated animals revealed
that PHDi treatment induced significant increases in both
ITF (Po0.05) and CD73 (Po0.05) at day 7 compared
with untreated controls (Figure 3c). Likewise, examination
of the wound healing–associated HIF target gene, b1 integrin
(ITGB1),7 revealed an early increase in response to AKB-4924
(Figure 3d, day 3, Po0.05 compared with vehicle control),
which had resolved by day 7 (P-value not significant compared
with vehicle).We next assessed the relative expression ofHIF in
epithelial and lamina propria cells from control and TNBS
colitis animals in the presence AKB-4924. Nuclear isolates
from enriched intestinal epithelial cells and epithelial-
denuded lamina propria tissue were examined for HIF-1a
by western blot and revealed a preferential stabilization of
HIF-1a in intestinal epithelial cells of animals treated with
AKB-4924 (Figure 3e).
In order to assess whether the serum LPS was a result of
bacterial translocation across the epithelium, we isolated and
cultured total colony-forming units (CFU) of aerobic bacterial
populations from the blood, mesenteric lymph nodes, liver,
spleen, and kidneys of TNBS colitis animals treated with PHDi
or vehicle. There was a significant decrease in recovered viable
bacteria in the blood and organs of TNBS colitis animals
treated with AKB-4924, compared with vehicle control
(Figure 4a). Non-colitic animals demonstrated negligible
bacterial translocation to extra-intestinal organs (data not
shown).
Given the level of translocated viable bacteria entering the
circulation in colitic animals and based on previous studies
demonstrating that another PHDi, DMOG, increased the
phagocytic capacity of neutrophils,12 we investigated whether
AKB-4924 influenced the capacity of leukocytes to phagocytose
bacteria. Isolated mouse neutrophils andmacrophages demon-
strated an increased phagocytosis of heat-inactivated Escher-
ichia coli (Figure 4b,Po0.05). Together, these data suggest that
themucosal protection afforded by treatment is multi-factorial,
enhancing both epithelial barrier function and leukocyte
phagocytosis.
Epithelial HIF-1a is required for PHDi-induced mucosal
protection in TNBS colitis
Guided by our results that PHDi preferentially stabilized
epithelial HIF and barrier function is enhanced by PHDi,
we examined the relative importance of intestinal epithelial
HIF-1a. To achieve this, we utilized intestinal epithelial-specific
Hif1a-deficient mice.21 As shown in Figure 5a, and as we
have shown in the past,21 HIF-1a is stabilized by colitis
induction using TNBS. The addition of AKB-4924 signi-
ficantly enhanced such induction (Figure 5a) with essentially
undetectable levels in intestinal epithelial-specific Hif1a-
deficient mice.
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Figure 3 Influence of AKB-4924 on intestinal epithelial barrier function
andhypoxia-inducible factor (HIF) target geneexpression.AKB-4924 (0 or
5.0mg kg1 in cyclodextrin vehicle) was administered subcutaneously on
day  1 relative to trinitrobenzenesulfonic acid (TNBS) orEtOH intrarectal
lavage. Animalswere killed ondays2, 3, or 7, and colonswereexcisedand
tied off by suture into intestinal sacs. Sacs were loaded with fluorescein
isothiocyanate-dextran 4400 (FD-4; 500 mgml1) and (a) the apparent
permeability (Papp) was assessed. Blood was collected by sterile cardiac
puncture and (b) serum assayed for lipopolysaccharide (LPS) content.
Colon epithelial mRNA was screened by quantitative PCR for induction of
the HIF-target genes CD73 and (c) intestinal trefoil factor (ITF) or (d) b1
integrin (ITGB1). Panel (e) represents western blot analysis for HIF-1a in
nuclear isolates from intestinal epithelial cells (IEC) and lamina propria
(LP) cells in control andTNBScolitis animals in the presenceofAKB-4924.
TATA-binding protein was employed as a housekeeper. N¼ 6, *, ^,
#Po0.05; **, ^^, ##Po0.01; analysis of variance (a, b, d), two-tailed,
Student’s t-test (c).
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To define the functional contribution of epithelial HIF-1a, we
examined whether PHDi treatment protected intestinal epithe-
lial-specific Hif1a-deficient mice from TNBS colitis. Consistent
with previous studies,21 intestinal epithelial-specific HIF-1a-
deficient mice developed more severe colitis than wild-type
animals as measured by weight loss (Figures 5b, Po0.01) and
colon shortening (Figure5c,Po0.025). Importantly,AKB-4924
did not significantly influence the course of disease in epithelial-
specific HIF-1a-deficient mice (P-value not significant for
weight loss or colon length). Together, these data suggest that
epithelial HIF-1a-mediated effects are central to the protective
actions of PHDi treatment in colitis. These findings suggest
that PHDi treatment potently augments and increases
restitution of intestinal barrier function, thereby significantly
limiting the passage of bacterial products across the mucosa.
AKB-4924 promotes remission in established TNBS colitis
Given that PHDi treatment suppressed inflammatory cytokine
activity, we hypothesized that treatment could promote
remission of active murine colitis. Colitic mice were treated
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with PHDi or vehicle at the peak of acute disease (day 2).
PHDi-treated animals showed significant weight gain within
48 h (Figure 6a) and had comparable weight, colon length
(Figures 6b, Po0.05) and lymph node cellularity (Figure 6c,
Po0.05) than controls 5 days post treatment. PHDi treatment
also significantly reduced disease activity score compared with
untreated animals (Figure 6d, Po0.05). In addition, PHDi-
treated animals did not develop hypothermia and temperatures
returned to baseline over the course of treatment, in contrast to
vehicle-treated animals that developed hypothermia as disease
progressed (Figure 6e, Po0.05). Upon examination of serum
cytokine levels, AKB-4924 suppressed the levels of the major
pyrogens IL-1b (Po0.01), IL-6 (Po0.01), and TNF-a
(Po0.01) (data not shown) compared with vehicle-treated
TNBS animals. These data demonstrate that PHDi treatment
can reverse acute inflammatory colitis.
AKB-4924 is protective in a spontaneous TNF-a-mediated
transgenic mouse model of ileitis
To determine the universality of our observed protection
afforded by AKB-4924, we extended these studies to a genetic
mouse model of spontaneous intestinal inflammation. To do
this, we assessed the therapeutic potential of AKB-4924 in the
TNFDAREmouse model.22 These mice spontaneously develop
transmural Crohn’s disease–like chronic inflammation in the
terminal ileum. Ten-week-old TNFDARE mice were treated
every second day for 10 days withAKB-4924 (0.5mg permouse
per dose intraperitoneally). As determined by quantitative
histological examination, treatment of these animals withAKB-
4924 revealed significant decreases in overall histopathology
(Figure 7a), acute (Figure 7b) and chronic inflammation
(Figure 7c), villus distortion (Figure 7d), and overall
inflammatory indices (Figure 7e). These findings suggest
that attenuation of inflammation by PHDi is not limited to
chemically induced colitis models and is broadly protective in
different models of intestinal inflammation.
DISCUSSION
This study aimed to clarify the relative role of innate immunity
to mucosal protection afforded by a new HIF-1a isoform-
predominant PHDi, AKB-4924, in mouse models of intestinal
inflammation. Previous work has demonstrated that
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pharmacological HIF stabilization offers protection to the
mucosal barrier6,9 and that HIF promotes barrier restitution,20
cell survival,8 and accelerates the healing process7 in models of
murine colitis. Here, we extended these studies by demonstrat-
ing that a PHDi promotes innate immunity, and suppresses
the pyrexic response in vivo during colitis. We show that
pharmacological HIF-1 stabilization enhances epithelial barrier
function and diminishes endotoxemia associated with
increased bacterial translocation in colitis. Studies in condi-
tional Hif1a-null animals revealed a central role for intestinal
epithelial HIF-1a in mucosal protection associated with PHDi-
based therapeutic strategies.
IBD are characterized by repeated wounding of the mucosa,
loss of the intestinal epithelial barrier, inflammation and
ultimately bacteremia. Indeed, IBD patients have increased
intestinal permeability23–25 and elevated levels of serum
endotoxin.3,26,27 This is mirrored in experimental models
of colitis, where serum endotoxin drives the secretion of
pyrogens28 leading to early pyrexia and later onset of
hypothermia.18 We observed an early pyrogenic response in
animals with TNBS colitis, coupled with increased serum levels
of classical pyrogens IL-1b, IL-6, and TNF-a. This is likely to be
driven by significantly increased intestinal permeability leading
to elevated serum LPS. PHDi treatment of mice with TNBS-
induced colitis led to reduced intestinal permeability and
significantly lower levels of serum LPS. Interestingly, treated
animals did develop some pyrexia and exhibited early increases
in pyrogens, although this was significantly lower than in
untreated controls, suggesting that sufficient endotoxin expo-
sure occurred to induce fever. However, treatment prevented
the development of hypothermia, which was concurrent with
the suppression of serum pyrogens and secretion of IL-10. This
led us to investigate whether HIF activation directly regulated
innate responses that were driven by LPS exposure.
Hypoxia occurs concurrently with inflammatory responses
in IBD and colitis inmice, most likely through the combination
of increased metabolic demands of inflamed tissue and altered
blood flow that results from tissue damage.29–31 It is now
accepted that HIF has an important role in regulating immune
cell function and suppressing inflammation. Furthermore, the
induction of HIF promotes the bactericidal activities of
phagocytic cells13,32 and supports the innate immune functions
of dendritic cells,33 mast cells,34 and epithelial cells.7,35 The role
of HIF in immune cell regulation is unsurprising, given the
steep oxygen gradient between healthy and inflamed tissue. The
oxygen content of healthy tissues typically range from 2.5% to
9%oxygen,whilemarkedly lower levels (o1%oxygen) occur in
inflamed sites.36 In order to function in these hypoxic
environments, immune cells can adapt to hypoxia, and indeed,
hypoxia-drivenHIF signaling appears to be an important input
signal for innate immune defense.
It is now accepted that HIF is the major transcriptional
regulator of epithelial compensatory pathways in hypoxia,
including the induction of HIF-target genes ITF,19 CD73,20 and
the adenosine A2B receptor.37 Stabilization of HIF by
inhibition of PHD has been shown to drive the expression
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of these barrier-protective genes6,38 and also to promote
restitution of the damaged mucosa through induction of the
ITGB1.7 In addition, PHDi-driven nuclear factor-kB activation
has been demonstrated to promote anti-apoptotic gene
expression in epithelial cells,8 and it is proposed that the
culmination of these pathways leads to the mucosal protection
promoted by PHDi in models of IBD.38 In our studies, AKB-
4924 preferentially stabilized HIF-1a in intestinal epithelial
cells. In addition, AKB-4924 offered no protection to TNBS
colitis in a mouse strain with a targeted epithelial deletion of
HIF-1a. In wildtype TNBS mice treated with AKB-4924,
isolated epithelial cells showed induction of ITF and CD73,
while the kinetics of ITGB1 expression were accelerated,
suggesting earlier epithelial restitution. Thus it appears that
while HIF induction in leukocytes may augment innate
responses to bacteremia during mucosal inflammation, the
loss of barrier function, or perhaps critically, the loss of
reparative pathways, will eventually overwhelm the innate
immune system. The observation that AKB-4924 reduced
mucosal inflammation in TNFDARE mice supports these
findings. These animals display a translational dysregulation of
TNF message, resulting in TNF-a overproduction and loss
of TNF-driven modulation of hemopoietic cells22 that are
important in the maintenance of gastrointestinal immunolo-
gical homeostasis.
In summary, we have demonstrated that systemic admin-
istration of PHDi suppresses inflammatory signaling and
promotes increased phagocytosis of bacteria, protecting against
colitis-induced bacteremia. It is likely that the prevention of
serosal exposure to the luminal contents, through increased
epithelial barrier function and accelerated wound healing, is
central to the protection by PHDi observed inmurinemodels of
colitis.
METHODS
Animalmodelsof colitis. Age-matched (6-week old), female C57BL/6
mice were housed for 1 week to allow microflora equilibration. Mice
were anesthetized with isoflourane, shaved, and sensitized by epi-
cutaneous application of 1% TNBS (Sigma Chemical, St Louis, MO) in
100% ethanol. After 7 days, mice were again anesthetized with
isoflourane and intrarectally administered 5 ml per g body weight of a
2.5% TNBS solution as previously described.6 Vehicle-treated control
animals received an equivalent volume of 50% ethanol alone. Mice
were monitored for development of disease over 7 days. In some
experiments, mice lacking intestinal epithelialHif1a expression21 were
used to determine HIF isoform specificity. TNFDARE mice were
housed for 10 weeks under specific pathogen-free conditions as
previously described.39
The PHDiAKB-4924 (Aerpio Therapeutics, Cincinnati, OH, (0.3, 1,
or 5mg kg 1)) was administered daily via 100-ml subcutaneous
injection to the scruff. Control was 100-ml cyclodextrin vehicle. Mice
were monitored daily, and all protocols were performed in strict
adherence with institutional animal ethics guidelines. Animals’
weights were monitored every 24 h over the course of the experiment
from day  1 relative to TNBS induction. Temperature was measured
via infrared thermometer during the course of disease and treatment.
Sample analysis. Colons were excised and divided for protein,
mRNA, and histological analysis. Samples for protein analysis were
stored in Tris-lysis buffer, mRNA was isolated by Trizol mRNA
isolation, and histological samples were fixed in 4% formalin. In
subsets of experiments, intestinal epithelial cells were isolated for
mRNAanalysis as previously described.40Western blotting forHIF-1a
was performed as previously described.21 Blood was collected by
cardiac puncture. Serum, mRNA, and protein samples were stored at
 80 1C until analysis. Protein analysis of serum and colon tissue was
carried out by Mesoscale high-sensitivity or conventional ELISA.
mRNA analysis was performed by real-time-PCR assays using pre-
viously validated primers for CD73,21 ITF,21 and ITGB1.7 Serum
endotoxin levels were assessed using colorimetric assays according to
the manufacturer’s instructions (QCL-1000, Lonza Inc., Walkersville,
MD).
Permeability assays. Permeability assays were conducted with
intestinal tissue sacs based on previously described assays.41 Briefly, at
each end point, animals were euthanized and mouse colons were
excised and flushed with oxygenated TC199medium. The colons were
tied tightly at one end with silk suture and a small animal vascular
catheter (Data Sciences International Physiocath 277-1-002, New
Brighton, MN) was tied in to the other end to form an intestinal sac.
Each colon yielded two sacs, 2 cm long. A 1-ml syringe with a sterile 26
gauge micro lance was fixed to the catheter and 250 ml of FD-4
(1.0mgml 1) was injected into each sac lumen. Each sac was placed
into separate 50-ml conical tubes containing 15ml of oxygenated TC-
199mediumon a shakingwater bath for 120min at 37 1C, according to
the method of Barthe et al.42 Samples (120 ml) were collected from the
bath every 15min and replaced with fresh medium. After 120min, the
sacs were cut open and the contents sampled. FD-4 concentration was
calculated from fluorescent standard curves (Spectramax m5e,
Molecular Devices Inc., Sunnyvale, CA). The velocity of FD-4 across
the intestinal barrier; the apparent permeability (Papp) for FD-4, was
calculated from the following equation:
Papp cm s 1
 ¼ dQ=dtð Þ= ACoð Þ;
where dQ/dt is the transport rate (mol s 1 of FD-4), A is the surface
area of the monolayer or sac (cm2), and Co is the initial concentration
in the donor compartment (molml 1).41,43,44
Leukocyte isolation phagocytosis assays. To isolate murine
neutrophils and macrophages, C57BL/6 mice were administered 1ml
of 3% sterile thioglycolate (Sigma) intraperitoneally as previously
described.45–47 For neutrophil isolation, animals were killed after 6 h,
and peritoneal lavage was performed using 10ml of endotoxin-free
phosphate-buffered saline. The lavage fluid was centrifuged at 600 g
for 10min. Total cells were enumerated using a hemocytometer and
neutrophils were enumerated (490%) by Wright–Giemsa staining.
For macrophage isolation, the assay was performed as above, but
animals were lavaged 72 h after thioglycolate administration.
For phagocytosis assays, E. coli were cultured to log phase in LB
(lysogeny broth) broth, heat inactivated at 60 1C for 1 h, and labeled
with fluorescein isothiocyanate as previously described.12 Isolated
phagocytes were equilibrated in hypoxia or normoxia, with or without
10 mMAKB-4924 for 1 h before the addition of bacteria at a ratio of 1:10
for a further hour. Cells were then pelleted, washed, and extracellular
fluorescein isothiocyanate was quenched with Trypan blue. Fluor-
escence was assayed in a 96-well fluorometric plate reader and the
percentage phagocytosis calculated, relative to the inoculum.
Microbiologicalanalysis. Detection of viable enteric bacteria in extra-
intestinal organs was performed by organ culture and CFU count.48,49
Samples of mesenteric lymph nodes, liver, kidney, and spleen were
removed under sterile conditions immediately upon euthanasia.
Tissueswere dissected free from fat, weighed, andhomogenized in 5ml
of sterile phosphate-buffered saline. Serial dilutions of homogenates
were plated onMacConkey and blood agar plates and incubated for up
to 72 h at 37 1C. After incubation, CFU were counted and adjusted
by tissue sample weight (CFU g 1). Blood samples were obtained by
sterile cardiac puncture, aseptically diluted in brain heart infusion
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broth, cultured for 48 h, and plated as above. Viable bacteria counts
were expressed as CFU per ml blood.
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